Status:
COMPLETED
The Pharmacokinetics and Effectiveness of Local LevoBupivacaine Injection on Primary Total Joint Replacement Model.
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Arthropathy
Eligibility:
All Genders
50-80 years
Phase:
NA
Brief Summary
Total joint replacement is an ideal procedure to treat end stage joint disease. Good post-op pain relief could accelerate patient recovery and rehabilitation, and decrease admission days and medical c...
Detailed Description
Single large dose of LevoBupivacaine had been proved good analgesic effect in total joint replacement surgery. However, the safety was not well studied. For better understanding the effect and safety ...
Eligibility Criteria
Inclusion
- Primary total joint replacement, no previous open surgery on the same joint
- Age 50\~80 y/o, Pre-operative diagnosis: degenerative osteoarthritis
- Pre-operative deformity: varus \<15°, valgus \<15°, flexion contracture \<15°.
- Patients with normal heart function
- Willing to receive post-operative questionnaire and outpatient clinic follow-up
Exclusion
- Allergy to Patient-Controlled Analgesia or LevoBupivacaine
- Mental or cognitive illness that couldn't well response to questionnaire
- American Society Anesthesiologist more than III degree
- Liver cirrhosis, chronic renal insufficiency, heart disease or arrhythmia, insulin-dependent diabetes mellitus, and previous narcotic abuse history.
- Not suitable for using patient-controlled analgesia pump by evaluation of anesthesiologist
Key Trial Info
Start Date :
October 17 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2019
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT03258697
Start Date
October 17 2017
End Date
May 31 2019
Last Update
June 4 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital, Linkou
Taoyuan, Taiwan, 333